Volker Schellenberger is the founder of Amunix. Amunix has raised $193M in total funding. Latest round: Series B. Based in South San Francisco, California.
Volker Schellenberger, Ph.D., served as President and CEO of Amunix Pharmaceuticals, an immuno-oncology company focused on developing prodrugs and T-cell engagers for cancer patients. He later held the role of President and Chief Technology Officer (CTO) at Amunix before the company was acquired by Sanofi in 2022.
Full founder directory · Investor directory · Company funding database · Fundraising library